RxDoctor Payments Data

Seth Stephenson

Nurse Practitioner · Mason, OHNPI 1164778924

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Amgen at 57.1% of the total. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$45,475in general payments, 2019–2025

Across 874 payments — averaging $52.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$26K
  • AbbVie$3K
  • Johnson & Johnson$3K
  • Incyte Corporation$2K
  • Lilly USA, LLC$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • plus $9K from 24 others

What the payments were for

  • Consulting fees$1,1252%
  • Speaking & faculty fees$23,29351%
  • Travel & lodging$3411%
  • Food & beverage$20,17444%
  • Education$5411%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,475 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$200,302
Medicare patients
817
Services billed
4,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast16$76,088
Dupixent PenDupilumab20$74,660
Fluocinonide64$2,218
Metronidazole37$2,092
Clobetasol Propionate75$1,884
Triamcinolone Acetonide100$1,276
Ketoconazole93$1,165
Fluorouracil19$1,105
Doxycycline Hyclate65$1,023
Desonide17$1,020
Clindamycin Phosphate27$1,011
Doxycycline Monohydrate22$559
Mupirocin33$181
Hydrocortisone12$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$25,973$76,08816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Mason

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →